A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial

EuroIntervention 2018;14:692-699 published online December 2017. DOI: 10.4244/EIJ-D-17-00734

Juan F. Iglesias
Juan F. Iglesias1, MD; Olivier Muller2*, MD, PhD; Serge Zaugg3, MSc; Marco Roffi1, MD; David J. Kurz4, MD; André Vuilliomenet5, MD; Daniel Weilenmann6, MD; Christoph Kaiser7, MD; Maxime Tapponnier8, MD; Dik Heg3, PhD; Marco Valgimigli9, MD, PhD; Eric Eeckhout2, MD, PhD; Peter Jüni10, MD; Stephan Windecker9, MD; Thomas Pilgrim9, MD
1. Cardiology Division, University Hospital, Geneva, Switzerland; 2. Cardiology Department, University Hospital, Lausanne, Switzerland; 3. Clinical Trials Unit Bern, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 4. Ca

Aims: A novel ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES) (Orsiro; Biotronik, Bülach, Switzerland) was shown to be superior to a thin-strut durable polymer ever

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

clinical researchstemithrombus-containing lesion
Read next article
Impact of diagnostic ECG-to-wire delay in STEMI patients treated with primary PCI: a DANAMI-3 substudy

Latest news